Moderna doses first patient in Phase 1 trial of mRNA-4200 cancer therapy in solid tumors

Moderna

Moderna

MRNA

0.00
  • Moderna dosed the first U.S. participant in a Phase 1 trial of mRNA-4200, an off-the-shelf tumor-targeted cancer antigen therapy for solid tumors.
  • Study will assess safety and tolerability of mRNA-4200 given with checkpoint inhibitor therapy in adults with advanced or metastatic solid tumors.
  • mRNA-4200 encodes seven shared tumor antigens, aiming to induce and expand T-cell responses across multiple tumor types.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202607160700ACCESSWRNAPR_____1190971) on July 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.